AVBP — ArriVent Biopharma Balance Sheet
0.000.00%
Annual balance sheet for ArriVent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 37.3 | 163 | 150 | 219 | 313 |
| Net Total Receivables | 0.25 | 0.5 | 0.761 | 0.5 | 0.06 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 43 | 183 | 160 | 227 | 333 |
| Net Property, Plant And Equipment | 0 | 0.139 | 0.291 | 0.154 | 0.013 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 43 | 183 | 163 | 275 | 333 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1.82 | 8.36 | 11.6 | 17.3 | 25.9 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.82 | 8.37 | 11.8 | 17.3 | 25.9 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 41.2 | 174 | 151 | 258 | 307 |
| Total Liabilities & Shareholders' Equity | 43 | 183 | 163 | 275 | 333 |
| Total Common Shares Outstanding |